Interest of monoclonal antibodies in the treatment of ventilator associated pneumonia
Anticorps monoclonaux et PAVM
Keywords:monoclonal antibodies, ventilator-associated pneumonia, antibiotics, infection, intensive care unit
The development of monoclonal antibodies (mAbs) in infectious diseases has increased in the last 10 years with several therapeutic indications, especially to prevent ventilator associated pneumonia (VAP). The latter remains a major concern in ICUs due to its important incidence, morbidity and related increased mortality. The use of mAbs for this indication has a particular interest, considering their safety profile, developed targets and wide range of intervention opportunities from preemption to adjunctive treatment.
This review aims to look over the main mAbs being tested for the treatment of VAP, their molecular targets and advantages and challenges in their current development.